Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid gets NICE nod

Executive Summary

UK's National Institute for Health and Clinical Excellence makes a preliminary positive recommendation for use of Celgene's Revlimid (lenalidomide) as a second-line therapeutic for multiple myeloma. After receiving the recommendation, the National Health Service is expected to make a final decision during the second quarter. If NHS agrees, it would fully fund use of oral Revlimid, given along with dexamethasone, for 26 treatment cycles of 28 days per cycle (normally two years). Celgene says it will pick up the tab for UK patients who choose to remain on the drug for longer. In the U.S., Revlimid is approved for treatment of MM patients who have received at least one prior therapy and for transfusion-dependent anemia in those with myelodysplastic syndromes. It also is listed on several compendia and used off-label in newly diagnosed MM patients (1"The Pink Sheet," Dec. 15, 2008, p. 11). The biologic hit $1.3 billion in worldwide sales in 2008. Celgene plans to file in the U.S. for approval as a front-line therapy for MM in 2009

Related Content

Topics

UsernamePublicRestriction

Register

PS050633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel